American Journal of Neuroradiology, Vol 16, Issue 3 543-553, Copyright © 1995 by American Society of Neuroradiology
ARTICLES |
MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy
S Roman-Goldstein, P Mitchell, JR Crossen, PC Williams, A Tindall and EA Neuwelt
Department of Diagnostic Radiology, Oregon Health Sciences University, Portland 97201-3098, USA.
PURPOSE: To determine whether osmotic blood-brain barrier disruption is associated with MR abnormalities or cognitive deterioration and, if so, whether the MR findings correlate with cognitive test results. METHODS: Fifteen brain tumor patients who had a complete tumor response (nine central nervous system lymphoma, three germ cell and two astrocytoma, and one primitive neuroectodermal tumor) treated with blood-brain barrier disruption procedures (318 total procedures) with intraarterial chemotherapy were included. MR images were evaluated for the development of white matter hyperintensity, vascular lesions, or atrophy. Cognitive testing was performed to assess deterioration caused by this therapy. RESULTS: In two patients white matter hyperintensity developed, in two small vascular lesions developed, and in one mild atrophy developed. One infarct was asymptomatic and the second one resulted in mild dysesthesia in one upper extremity. No patient showed diminished cognitive function on the posttherapy evaluation. CONCLUSION: In patients undergoing blood-brain barrier disruption with intraarterial chemotherapy, new abnormalities on MR imaging may develop. These patients maintain the same level of cognitive and neurologic function and MR findings do not correlate with the results of cognitive testing.
This article has been cited by other articles:
 |
|
 |
|
  L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Correa, L Maron, H Harder, M Klein, C. Armstrong, P Calabrese, J. Bromberg, L. Abrey, T. Batchelor, and D Schiff Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines Ann. Onc., July 1, 2007; 18(7): 1145 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Neuwelt, P. E. Guastadisegni, P. Varallyay, and N. D. Doolittle Imaging Changes and Cognitive Outcome in Primary CNS Lymphoma after Enhanced Chemotherapy Delivery AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 258 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Harder, H. Holtel, J. E.C. Bromberg, P. Poortmans, H. Haaxma-Reiche, H. C. Kluin-Nelemans, J. Menten, and M. J. van den Bent Cognitive status and quality of life after treatment for primary CNS lymphoma Neurology, February 24, 2004; 62(4): 544 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cucullo, N. Marchi, M. Marroni, V. Fazio, S. Namura, and D. Janigro Blood-Brain Barrier Damage Induces Release of {alpha}2-Macroglobulin Mol. Cell. Proteomics, April 1, 2003; 2(4): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Marchi, V. Fazio, L. Cucullo, K. Kight, T. Masaryk, G. Barnett, M. Volgelbaum, M. Kinter, P. Rasmussen, M. R. Mayberg, et al. Serum Transthyretin Monomer as a Possible Marker of Blood-to-CSF Barrier Disruption J. Neurosci., March 1, 2003; 23(5): 1949 - 1955. [Abstract] [Full Text] [PDF]
|
|